Efficacy and safety profiles of dolutegravir plus lamivudine vs. bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1

BACKGROUND: Dual regimen dolutegravir (DTG) plus lamivudine (3TC) has demonstrated non-inferior efficacy compared to DTG-based three-drug regimens (3DRs), yet directly comparative data regarding the efficacy and safety of DTG + 3TC and bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for th...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Yinghua, Li, Jin, Xu, Ruhong, Wen, Li, Deng, Yiming, He, Lixia, Zhong, Huijun, Wang, Yanhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684251/
https://www.ncbi.nlm.nih.gov/pubmed/37914678
http://dx.doi.org/10.1097/CM9.0000000000002907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684251/
https://www.ncbi.nlm.nih.gov/pubmed/37914678
http://dx.doi.org/10.1097/CM9.0000000000002907

Ejemplares similares